Table 2 Fold change of genes in PC3 cells exposed to combination treatment or mono-treatment with Taxotere or Furtulon
Gene | Taxotere | Furtulon | Taxotere+Furtulon | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | 6 h | 36 h | 72 h | 6 h | 36 h | 72 h | 6 h | 36 h | 72 h |
Cell cycle and apoptosis | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_001237.1 cyclin A2 (CCNA2) | NC | -1.1 | -2.0 | -1.1 | -1.7 | -3.0 | -1.1 | -1.4 | -2.5 |
BE407516 cyclin B1 | -1.1 | -1.1 | -2.3 | NC | -3.0 | -6.1 | -1.1 | -3.0 | -5.3 |
NM_001761.1 cyclin F (CCNF) | -1.3 | -1.3 | -2.5 | -1.5 | -2.5 | -2.6 | -1.6 | -1.6 | -2.5 |
NM_014303.1 pescadillo homolog 1 | NC | -1.5 | -2.3 | 1.3 | -1.9 | -2.6 | -1.1 | -2.1 | -3.5 |
NM_003132.1 spermidine synthase (SRM) | NC | -1.5 | -2.5 | -1.1 | -1.3 | -2.5 | -1.1 | -1.1 | -2.3 |
NM_000389.1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 1.7 | 1.0 | 2.6 | 1.9 | 2.6 | 3.5 | NC | 1.7 | 3.5 |
NM_003914.1 cyclin A1 (CCNA1) | 1.3 | 2.3 | 2.8 | NC | 1.5 | 2.5 | NC | NC | 2.0 |
L49506.1 cyclin G2 | -2.1 | 2.0 | 2.6 | -2.8 | 2.3 | 2.3 | NC | 3.7 | 2.5 |
NM_004354.1 cyclin G2 (CCNG2) | -1.9 | 3.0 | 3.2 | NC | 2.5 | 2.3 | 1.0 | 4.6 | 3.5 |
AL535380 B-cell translocation gene 1, anti-proliferative | 1.1 | 1.7 | 3.5 | NC | 1.4 | 2.8 | -1.5 | 1.6 | 2.6 |
NM_006472.1 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) | 1.3 | 2.1 | -2 | 1.0 | 2.1 | 2.3 | 1.0 | 2.3 | NC |
NM_015675.1 growth arrest and DNA-damage-inducible, beta (GADD45B) | 1.2 | 2.5 | 6.5 | 1.6 | 1.5 | 2.6 | 1.0 | NC | 3.5 |
AF087853.1 growth arrest and DNA damage inducible protein beta | NC | 2.0 | 4.6 | 1.3 | 1.2 | 2.3 | NC | NC | 3.2 |
AF078077.1 growth arrest and DNA-damage-inducible protein GADD45beta | 1.5 | 2.0 | 5.3 | 1.1 | 1.2 | 2.1 | NC | 1.4 | 2.8 |
Transcription and translation | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_007111.1 transcription factor Dp-1 (TFDP1) | NC | -1.6 | -3.2 | -1.3 | -1.1 | -2.0 | NC | -1.1 | -2.0 |
NM_012068.2 activating transcription factor 5 (ATF5) | NC | -2.1 | -3.5 | NC | -1.5 | -2.1 | -1.3 | -1.1 | -2.6 |
NM_012251.1 transcription factor A, mitochondrial (TFAM) | 1.3 | -1.5 | -2.5 | NC | -1.6 | -2.0 | -1.1 | -2.0 | -3.7 |
AF220509.1 transcription associated factor TAFII31L | NC | -2.3 | -3.2 | -1.3 | -1.3 | -2.3 | NC | -1.2 | -5.7 |
AA393940 eukaryotic translation initiation factor 5A | -1.3 | -1.5 | -3.0 | -1.6 | -2.0 | -3.5 | -1.1 | -1.1 | -2.0 |
NM_001674.1 activating transcription factor 3 (ATF3) | 1.4 | 1.9 | 14.9 | 1.5 | 2.1 | 3.5 | 1.1 | 2.6 | 4.9 |
Oncogenesis and other | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_001511.1 GRO1 oncogene (GRO1) | 2 | -1.5 | -3.0 | 1.7 | 1.2 | -2.0 | NC | NC | -4.0 |
NM_002090.1 GRO3 oncogene (GRO3) | 2.8 | -3.0 | -4.0 | 2.5 | -1.4 | -6.5 | NC | -2.8 | -13.9 |
NM_005754.1 Ras-GTPase-activating protein SH3-domain-binding protein | NC | -1.7 | -2.8 | NC | -2.0 | -2.5 | NC | -2.6 | -4.6 |
NM_000026.1 adenylosuccinate lyase (ADSL) | NC | -1.3 | -2.5 | NC | -1.4 | -2.6 | NC | -1.6 | -3.0 |
M80261.1 apurinic endonuclease (APE) | -1.1 | -1.4 | -3.0 | -1.1 | -1.9 | -2.6 | NC | -2.1 | -3.7 |
D13413.1 tumor-associated 120 kDa nuclear protein p120 | -1.1 | -2.0 | -3.2 | -1.7 | -1.7 | -2.5 | -2.3 | -1.1 | -3.0 |
AI743685 methionine aminopeptidase; eIF-2-associated p67 | NC | -2.6 | -2.0 | 1.5 | -1.5 | -3.2 | NC | -2.3 | -2.8 |
NM_002634.2 prohibitin (PHB) | NC | -1.4 | -3.0 | NC | -1.9 | -2.1 | NC | -1.5 | -2.6 |
NM_002546.1 osteoprotegerin | 1.5 | -1.3 | -3.0 | 1.2 | -2.1 | -3.0 | NC | -2.8 | -5.3 |
AF003934.1 prostate differentiation factor mRNA | -1.5 | 4.3 | 26.0 | -1.7 | 4.9 | 16.0 | NC | 4.3 | 12.1 |
NM_000177.1 gelsolin (amyloidosis, Finnish type) (GSN) | NC | 1.5 | 2.8 | NC | 2.0 | 3.5 | NC | 1.9 | 2.3 |
Invasion and metastasis | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_003254.1 tissue inhibitor of metalloproteinase 1 (TIMP1) | NC | 2.0 | 2.5 | NC | 2.6 | 3.7 | NC | 2.6 | 3.7 |
NM_003255.2 tissue inhibitor of metalloproteina(TIMP2) | NC | 1.6 | 2.5 | NC | 2.3 | 3.5 | NC | 1.6 | 3.5 |
NM_002638.1 protease inhibitor 3 (PI3) | 1.2 | 2.0 | 2.0 | 1.1 | 3.7 | 5.7 | 1.0 | 3.0 | 4.6 |
NM_005562.1 laminin, gamma 2 (nicein (100 kD) | 1.3 | 1.5 | 2.0 | 1.1 | 2.5 | 3.7 | NC | 2.3 | 3.7 |
NM_001908.1 cathepsin B (CTSB) | NC | 1.7 | 3.0 | NC | 1.7 | 2.8 | 1.1 | 1.3 | 2.5 |
NM_002658.1 plasminogen activator, urokinase (PLAU) | NC | 2.3 | 3.5 | NC | 2.8 | 2.3 | 1.0 | 2.1 | 1.9 |
NM_000930.1 plasminogen activator, tissue (PLAT) | 1.1 | 2.5 | 4.6 | NC | 5.7 | 9.8 | NC | 3.2 | 4.9 |
NM_002421.2 matrix metalloproteinase 1 (MMP1) | NC | 1.4 | 4.3 | NC | 4.9 | 18.4 | NC | 5.7 | 13.0 |
NM_004994.1 matrix metalloproteinase 9 (MMP9) | 1.1 | 1.7 | 2.0 | 1.0 | 1.9 | 2.0 | NC | 2.5 | 2.1 |
NM_000435.1 Notch homolog 3 (NOTCH3) | NC | 2.0 | 2.6 | -2 | 2.3 | 3.2 | NC | 3.5 | 3.5 |
Resistance to chemotherapeutic agents | Â | Â | Â | Â | Â | Â | Â | Â | Â |
NM_000499.2 cytochrome P450, subfamily I (CYP1A1) | 1.4 | 3.0 | 4.0 | NC | 3.5 | 5.3 | 1.2 | 9.2 | 10.6 |
NM_006697.1 cisplatin resistance associated (CRA) | 1.0 | 1.7 | 2.0 | -1.3 | 2.0 | 2.6 | NC | NC | 2.6 |
NM_005980.1 S100 calcium-binding protein P (S100P) | -1.2 | 4.9 | 24.3 | 1.1 | 10.6 | 27.9 | NC | 6.5 | 19.7 |
NM_002961.2 S100 calcium-binding protein A4 (S100A4) | 3.0 | 3.7 | 5.3 | 1.0 | 5.7 | 11.3 | 2.8 | 6.5 | 10.6 |
NM_020672.1 S100-type calcium binding protein A14 (LOC57402) | NC | 1.5 | 2.0 | NC | 2.1 | 2.6 | 1.1 | 1.6 | 2.1 |
NM_001894.1 casein kinase 1, epsilon (CSNK1E) | NC | 1.7 | 3.2 | NC | 2.0 | 2.6 | 1.1 | 1.7 | 3.2 |
NM_000700.1 annexin A1 (ANXA1) | NC | 1.9 | 2.3 | NC | 2.0 | 2.3 | NC | 1.6 | 2.1 |